Acute Myocardial Infarction (AMI)NCT07471763
Prospective Lifespan Cohort of Myocardial Infarction
An observational study of Acute Myocardial Infarction (AMI) and Stable Angina, run by Fujian Provincial Hospital at 1 site in China.
Trial summary
This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Read more about this study
- Who is it for?
- Ages 18 to 74 years
- Conditions the study is for
- Acute Myocardial Infarction (AMI), Stable Angina, Unstable Angina
- How many people
- 6,000 participants
- Where
- 1 siteChina
- Study dates
- 10 Apr 2026to 10 Apr 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 74 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults aged 18 to 74 years will be enrolled into two cohorts: a high-risk population cohort including individuals with stable angina or unstable angina, and a confirmed acute myocardial infarction cohort including patients diagnosed according to the Fourth Universal Definition of Myocardial Infarction. All participants must be able to provide informed consent and complete baseline assessment, biospecimen collection, and longitudinal follow-up.
Who may be able to join
- Age 18 to 74 years
- Diagnosed with stable angina, unstable angina, or acute myocardial infarction
- For acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized
- Diagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction
- Willing to participate and able to provide written informed consent
- Able to complete baseline assessment, biospecimen collection, and long-term follow-up
Who cannot join
- End-stage malignant tumor with expected survival of less than 1 year
- Severe hepatic or renal dysfunction (estimated glomerular filtration rate <30 mL/min/1.73 m² or Child-Pugh class C)
- Active autoimmune disease or long-term use of immunosuppressive agents
- Pregnant or breastfeeding women
- Inability to provide informed consent or severe cognitive impairment
- Previous participation in another clinical study that may conflict with this project
- Any other condition considered by the investigators to make participation inappropriate
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Fuzhou University Affiliated Provincial Hospital
Fuzhou, Fujian, 350001
Kaiyang Lin, PhD, +86 13559355708, lky7411@sina.com
About this study
Official title: A Prospective Lifespan Cohort Study of Myocardial Infarction for Building an Integrated Multidimensional Database and Developing an Artificial Intelligence- and Multi-omics-Driven Precision Prevention and Control System
This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management.
The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up.
The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.
- Keywords
- prospective cohort, multi-omics, artificial intelligence, risk prediction, precision medicine, acute myocardial infarction, lifespan cohort
- Medical subject headings
- Angina, Stable, Angina, Unstable
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| High-risk Population | Participants at high risk of acute myocardial infarction, including individuals with stable angina or unstable angina, with or without silent myocardial ischemia, who undergo baseline assessment, biospecimen collection, and longitudinal follow-up. | |
| Confirmed Acute Myocardial Infarction Population | Participants with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction, including type 1, 2, 3, 4a, 4b, 4c, and 5 myocardial infarction, as well as myocardial infarction with non-obstructive coronary arteries when applicable, who undergo baseline assessment, biospecimen collection, and longitudinal follow-up. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of all-cause mortality
Measured: From enrollment to the end of study follow-up, up to 5 years
Secondary outcomes (7)
Rate of cardiovascular death
Measured: From enrollment to the end of study follow-up, up to 5 years
Rate of recurrent myocardial infarction
Measured: From enrollment to the end of study follow-up, up to 5 years
Rate of readmission due to heart failure
Measured: From enrollment to the end of study follow-up, up to 5 years
Rate of target vessel or non-target vessel revascularization
Measured: From enrollment to the end of study follow-up, up to 5 years
Rate of stroke
Measured: From enrollment to the end of study follow-up, up to 5 years
Rate of definite or probable stent thrombosis
Measured: From enrollment to the end of study follow-up, up to 5 years
Rate of severe bleeding
Measured: From enrollment to the end of study follow-up, up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Mar 2026
- Study start10 Apr 2026 (estimated)
- Primary completion10 Apr 2031 (estimated)
- Study completion10 Apr 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myocardial Infarction (AMI)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 6,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fujian Provincial Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kaiyang Lin, Fujian Provincial Hospital
- Investigators
- Kaiyang Lin, PhD, Principal investigator, Fuzhou University Affiliated Provincial Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07471763
- Sponsor's protocol ID
- K2026-03-001
- Status last verified
- Mar 2026
- First submitted
- 10 Mar 2026
- Last updated
- 25 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 25 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Lifespan Cohort Study of Myocardial Infarction for Building an Integrated Multidimensional Database and Developing an Artificial Intelligence- and Multi-omics-Driven Precision Prevention and Control System
- ClinicalTrials.gov ID
- NCT07471763
- Acronym / sponsor ID
- K2026-03-001
- Keywords
- prospective cohort, multi-omics, artificial intelligence, risk prediction, precision medicine, acute myocardial infarction, lifespan cohort
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 6,000 participants (estimated)
- Lead sponsor
- Fujian Provincial HospitalUniversity, hospital or other
- Study start
- 10 Apr 2026 (estimated)
- Primary completion
- 10 Apr 2031 (estimated)
- Study completion
- 10 Apr 2031 (estimated)
- First posted
- 13 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management.
The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up.
The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| High-risk Population | – | –Participants at high risk of acute myocardial infarction, including individuals with stable angina or unstable angina, with or without silent myocardial ischemia, who undergo baseline assessment, biospecimen collection, and longitudinal follow-up. |
| Confirmed Acute Myocardial Infarction Population | – | –Participants with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction, including type 1, 2, 3, 4a, 4b, 4c, and 5 myocardial infarction, as well as myocardial infarction with non-obstructive coronary arteries when applicable, who undergo baseline assessment, biospecimen collection, and longitudinal follow-up. |
Who may qualify
- Ages
- 18 to 74 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults aged 18 to 74 years will be enrolled into two cohorts: a high-risk population cohort including individuals with stable angina or unstable angina, and a confirmed acute myocardial infarction cohort including patients diagnosed according to the Fourth Universal Definition of Myocardial Infarction. All participants must be able to provide informed consent and complete baseline assessment, biospecimen collection, and longitudinal follow-up.
Key inclusion criteria (6 listed)
- Age 18 to 74 years
- Diagnosed with stable angina, unstable angina, or acute myocardial infarction
- For acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized
- Diagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction
- Willing to participate and able to provide written informed consent
Key exclusion criteria (7 listed)
- End-stage malignant tumor with expected survival of less than 1 year
- Severe hepatic or renal dysfunction (estimated glomerular filtration rate <30 mL/min/1.73 m² or Child-Pugh class C)
- Active autoimmune disease or long-term use of immunosuppressive agents
- Pregnant or breastfeeding women
- Inability to provide informed consent or severe cognitive impairment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Rate of all-cause mortality
Time frame: From enrollment to the end of study follow-up, up to 5 years
7 secondary outcomes
Rate of cardiovascular death
Time frame: From enrollment to the end of study follow-up, up to 5 years
Rate of recurrent myocardial infarction
Time frame: From enrollment to the end of study follow-up, up to 5 years
Rate of readmission due to heart failure
Time frame: From enrollment to the end of study follow-up, up to 5 years
Rate of target vessel or non-target vessel revascularization
Time frame: From enrollment to the end of study follow-up, up to 5 years
Rate of stroke
Time frame: From enrollment to the end of study follow-up, up to 5 years
Rate of definite or probable stent thrombosis
Time frame: From enrollment to the end of study follow-up, up to 5 years
Rate of severe bleeding
Time frame: From enrollment to the end of study follow-up, up to 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Mar 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Acute Myocardial Infarction (AMI)
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kaiyang Lin, PhD principal investigator
Fuzhou University Affiliated Provincial Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Myocardial Infarction (AMI) and Stable Angina, run by Fujian Provincial Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kaiyang Lin, PhD (+86 13559355708, lky7411@sina.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of all-cause mortality (time frame: From enrollment to the end of study follow-up, up to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2026; AzTrials last refreshed its copy on 8 Nov 2026.